Get the Stockscreener App
85.23
0.67%
0.57
After Hours:
85.23
Rhythm Pharmaceuticals Inc stock is traded at $85.23, with a volume of 472.99K.
It is up +0.67% in the last 24 hours and up +34.88% over the past month.
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. It is engaged in the development and commercialization of therapies for patients with rare diseases. The company is focused on its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. Geographically the company generates its revenue from the United States and internationally with the majority being generated from the United States.
See More
Previous Close:
$84.66
Open:
$83.98
24h Volume:
472.99K
Relative Volume:
0.68
Market Cap:
$5.42B
Revenue:
$136.86M
Net Income/Loss:
$-168.69M
P/E Ratio:
-30.33
EPS:
-2.81
Net Cash Flow:
$-113.49M
1W Performance:
-2.34%
1M Performance:
+34.88%
6M Performance:
+43.41%
1Y Performance:
+76.79%
1-Day Range:
$83.98
$86.67
1-Week Range:
$83.98
$87.34
52-Week Range:
$40.61
$94.80
Rhythm Pharmaceuticals Inc Stock (RYTM) Company Profile
Name
Rhythm Pharmaceuticals Inc
Sector
Industry
Phone
857-264-4280
Address
222 BERKELEY STREET, BOSTON, MA
Compare RYTM with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RYTM
Rhythm Pharmaceuticals Inc
|
85.23 | 5.59B | 136.86M | -168.69M | -113.49M | -2.81 |
|
VRTX
Vertex Pharmaceuticals Inc
|
456.87 | 120.48B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
545.46 | 59.88B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
392.24 | 44.31B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
670.33 | 36.65B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
301.13 | 32.46B | 3.81B | -644.79M | -669.77M | -6.24 |
Rhythm Pharmaceuticals Inc Stock (RYTM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-10-25 | Initiated | Goldman | Buy |
| Jul-07-25 | Initiated | Leerink Partners | Outperform |
| Apr-07-25 | Upgrade | BofA Securities | Neutral → Buy |
| Mar-05-25 | Resumed | Stifel | Buy |
| Jan-02-25 | Initiated | Jefferies | Buy |
| Dec-20-24 | Initiated | Oppenheimer | Outperform |
| Oct-21-24 | Initiated | Guggenheim | Buy |
| Sep-18-24 | Initiated | H.C. Wainwright | Buy |
| Sep-17-24 | Initiated | JMP Securities | Mkt Outperform |
| May-08-24 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-19-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Aug-01-23 | Upgrade | BofA Securities | Neutral → Buy |
| Jan-18-23 | Resumed | Canaccord Genuity | Buy |
| Aug-08-22 | Upgrade | Goldman | Neutral → Buy |
| Aug-05-22 | Upgrade | BofA Securities | Underperform → Neutral |
| Jun-17-22 | Reiterated | Needham | Buy |
| Mar-02-22 | Resumed | Stifel | Buy |
| Feb-17-22 | Upgrade | Ladenburg Thalmann | Neutral → Buy |
| Dec-08-21 | Initiated | Wells Fargo | Overweight |
| Nov-19-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Sep-14-21 | Resumed | Goldman | Neutral |
| Aug-04-21 | Downgrade | BofA Securities | Neutral → Underperform |
| Aug-04-21 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Nov-30-20 | Downgrade | BofA Securities | Buy → Neutral |
| Jan-08-20 | Initiated | Goldman | Sell |
| Jul-12-19 | Upgrade | Stifel | Hold → Buy |
| Jul-08-19 | Initiated | Canaccord Genuity | Buy |
| Mar-13-19 | Initiated | Ladenburg Thalmann | Buy |
| Sep-07-18 | Resumed | Morgan Stanley | Overweight |
| Jun-25-18 | Reiterated | Needham | Buy |
| Jun-15-18 | Reiterated | Needham | Buy |
| Oct-30-17 | Initiated | BofA/Merrill | Buy |
| Oct-30-17 | Initiated | Needham | Buy |
View All
Rhythm Pharmaceuticals Inc Stock (RYTM) Latest News
Loss-Making Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Expected To Breakeven In The Medium-Term - 富途牛牛
Rhythm pharmaceuticals exec Cramer sells $130k in shares By Investing.com - Investing.com India
Cramer, Rhythm Pharmaceuticals’ CHRO, sells $130k in shares By Investing.com - Investing.com Canada
Rhythm pharmaceuticals exec Cramer sells $130k in shares - Investing.com
Rhythm Pharmaceuticals Inc. At Decision Level — Rebound or ResistanceCapital Preserving Trade Plan Templates Shared - metal.it
Earnings Preview: Rhythm Pharmaceuticals, Inc. (RYTM) Q2 Earnings Expected to Decline - Yahoo Finance
Published on: 2025-07-29 04:03:24 - metal.it
Trendline Breach Raises Concern for Rhythm Pharmaceuticals Inc. InvestorsChart Driven High Reward Trading Setup Presented - metal.it
What are the latest earnings results for Rhythm Pharmaceuticals Inc.Expert Picks Insights For Fast Growth - jammulinksnews.com
What is Rhythm Pharmaceuticals Inc. company’s growth strategyFree Stock Market Return Analysis - jammulinksnews.com
Is Rhythm Pharmaceuticals Inc. stock overvalued or undervaluedInvest with confidence backed by data - jammulinksnews.com
Why is Rhythm Pharmaceuticals Inc. stock attracting strong analyst attentionCapitalize on market momentum for profits - jammulinksnews.com
How strong is Rhythm Pharmaceuticals Inc. company’s balance sheetIdentify breakout stocks before they peak - jammulinksnews.com
Rhythm Pharma Gets Price-Target Bump Ups To $129 After Oral Obesity Drug Impresses In Phase 2; Retail Appetite Swells - MSN
Is Rhythm Pharmaceuticals Inc. a growth stock or a value stockFree Stock Market Return Analysis - jammulinksnews.com
When is Rhythm Pharmaceuticals Inc. stock expected to show significant growthPhenomenal trading returns - jammulinksnews.com
Published on: 2025-07-27 20:42:04 - jammulinksnews.com
Published on: 2025-07-27 06:42:10 - metal.it
What drives Rhythm Pharmaceuticals Inc. stock priceTriple-digit wealth increases - PrintWeekIndia
Rhythm Pharmaceuticals Inc. Stock Analysis and ForecastUnstoppable trading performance - PrintWeekIndia
Is Rhythm Pharmaceuticals Inc. a good long term investmentDouble-digit growth - PrintWeekIndia
Rhythm Pharmaceuticals to Report Second Quarter 2025 Financial Results on Tuesday, August 5, 2025 - GlobeNewswire
Rhythm Pharmaceuticals Announces Q2 Earnings Date and Major Conference Appearance - Stock Titan
What analysts say about Rhythm Pharmaceuticals Inc. stockTremendous growth potential - jammulinksnews.com
Should You Invest in This Under-the-Radar Weight Loss Stock? - The Motley Fool
Rhythm Pharmaceuticals prices $175M stock offering - MSN
Rhythm Pharma Shares Soar After Experimental Drug Yields Weight Reduction In Brain-Damage Related Obesity - MSN
Why Rhythm Pharmaceuticals Inc. stock is on top investor watchlistsMoney Making Low Risk Plans - beatles.ru
Rhythm Pharmaceuticals CFO Sells 42,120 Shares - AOL.com
Rhythm Pharmaceuticals Q1 2025 Earnings: IMCIVREE Sales Reach $37.7M, Inventory Impact Affects Revenue, Cash on Hand Reaches $314.5M - AInvest
A Glimpse Into The Expert Outlook On Rhythm Pharmaceuticals Through 10 Analysts - Nasdaq
Canaccord Genuity raises Rhythm Pharmaceuticals stock price target on obesity treatment potential - Investing.com Canada
(RYTM) Investment Analysis - news.stocktradersdaily.com
How Rhythm Pharmaceuticals Inc. stock performs during market volatilityFree Consultation - beatles.ru
Rhythm Pharmaceuticals stock price target raised to $109 from $95 at BofA - Investing.com Canada
Rhythm Pharmaceuticals’ Promising MC4R Agonist Portfolio: Strong Phase 3 Results and Strategic Market Expansion - TipRanks
Rhythm Pharma gains as mid-stage trial for rare form of obesity succeeds - MSN
Rhythm Pharmaceuticals (NASDAQ:RYTM) Given a $110.00 Price Target by Oppenheimer Analysts - MarketBeat
Rhythm Pharmaceuticals Inc Stock (RYTM) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.43%
2.00%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):